Phosphatidylcholine for Health & Longevity - Quick Reference Sheet

Phosphatidylcholine for Health & Longevity

Created on 07/08/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 4.8 Audit

Phosphatidylcholine is the body's main carrier of choline, a nutrient central to liver function and brain signaling. Its clearest value is correcting a choline shortfall, which can reverse fat buildup in the liver. Benefits for gut and liver inflammation, memory, and heart concerns remain mixed or unproven. Overall, a low-risk nutrient with an unsettled broader case. (Full Review)

Protocol

Standard Dose
1–3 g/day
Oral phosphatidylcholine or essential phospholipids; European liver protocols ~1.8 g/day
Frequency
2–3× daily
Split dosing preferred over a single large dose
Timing
With meals
Taken with the largest meals; morning and evening split smooths mild cholinergic effect
Time to effect
Choline Status
Days–weeks
Choline-status and digestive effects
Liver Fat & Enzymes
8–24 weeks
Where liver-enzyme or fatty-liver changes occur
Cognition
Not reliable
Cognitive effects, if any, are not reliably seen

Benefits

Contraindications
  • Trimethylaminuria
  • Soy or egg allergy (source-dependent)
  • Advanced chronic kidney disease (stage 4–5, eGFR <30 mL/min)
  • Medically advised to limit choline
Key Interactions
  • Cholinergic drugs (donepezil, rivastigmine, galantamine)
  • Anticholinergic drugs (oxybutynin, scopolamine)
  • Other choline sources (CDP-choline, alpha-GPC, choline)
  • TMAO-raising supplements (L-carnitine, betaine, lecithin)
  • Fat-soluble drugs
  • Antibiotics

Risk & Side Effects

  • High: Gastrointestinal upset
  • Medium: Fishy body odor
  • Low: Cholinergic effects and hypotension at high parenteral doses; allergic reaction to the source material
  • Speculative: Cancer promotion via the TMAO pathway

Monitoring

Marker Target Why
ALT ~10–26 U/L (women), ~10–30 U/L (men) Tracks liver-cell injury and fatty-liver response
AST ~10–26 U/L Complements ALT for liver stress
GGT <20 U/L (women), <30 U/L (men) Sensitive marker of liver and bile stress
Homocysteine ≤7–8 µmol/L Reflects methylation balance affected by choline supply
Fasting lipid panel HDL-C >50 mg/dL; triglycerides <80 mg/dL Detects any lipid effect and cardiovascular context
TMAO Lower is better Gauges the gut-metabolite pathway of concern at higher doses

Cadence: Recheck at ~12 weeks after starting or changing dose, then every 6–12 months during continued use (every 3–6 months if liver disease or kidney impairment is present)

Qualitative Assessment

  • Energy and sense of digestive comfort
  • Cognitive clarity and memory (self-assessed)
  • Presence of any fishy body odor
  • Vividness or disruption of dreams